At close: June 14 at 4:00 PM EDT
After hours: June 14 at 4:23 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.95 | -0.96 | -3.93 | -3.89 |
| Low Estimate | -1.21 | -1.25 | -5 | -5.35 |
| High Estimate | -0.52 | -0.55 | -2.4 | -2.58 |
| Year Ago EPS | -56.75 | -9.34 | -49.12 | -3.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 5 | 5 |
| Avg. Estimate | 4M | -- | 8M | 6M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 20M | -- | 40M | 30M |
| Year Ago Sales | 688k | -- | 886k | 8M |
| Sales Growth (year/est) | 481.40% | -- | 802.90% | -25.00% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -4.5 | -0.84 | -0.78 | -1.17 |
| EPS Actual | -56.75 | -9.34 | -4.05 | -1.2 |
| Difference | -52.25 | -8.5 | -3.27 | -0.03 |
| Surprise % | -1,161.10% | -1,011.90% | -419.20% | -2.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.95 | -0.96 | -3.93 | -3.89 |
| 7 Days Ago | -0.95 | -0.96 | -3.93 | -3.89 |
| 30 Days Ago | -0.91 | -0.91 | -3.69 | -3.61 |
| 60 Days Ago | -0.89 | -0.96 | -3.52 | -3.13 |
| 90 Days Ago | -0.95 | -1.02 | -3.78 | -3.32 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SYRE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 98.30% | -- | -- | 8.40% |
| Next Qtr. | 89.70% | -- | -- | 11.00% |
| Current Year | 92.00% | -- | -- | 5.10% |
| Next Year | 1.00% | -- | -- | 12.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.36% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Wells Fargo: Overweight to Overweight | 5/13/2024 |
| Maintains | BTIG: Buy to Buy | 5/10/2024 |
| Initiated | Baird: Outperform | 5/2/2024 |
| Reiterates | Stifel: Buy to Buy | 3/26/2024 |
| Upgrade | Wells Fargo: Equal-Weight to Overweight | 3/1/2024 |
| Initiated | BTIG: Buy | 12/20/2023 |
Related Tickers
DNTH Dianthus Therapeutics, Inc.
26.00
-3.56%
APGE Apogee Therapeutics, Inc.
41.14
-4.59%
VRDN Viridian Therapeutics, Inc.
12.44
-5.40%
TCRX TScan Therapeutics, Inc.
8.40
-6.67%
PRAX Praxis Precision Medicines, Inc.
38.97
-2.70%
SWTX SpringWorks Therapeutics, Inc.
38.55
-1.51%
TRML Tourmaline Bio, Inc.
16.96
+2.17%
MLYS Mineralys Therapeutics, Inc.
12.58
-0.87%
LBPH Longboard Pharmaceuticals, Inc.
18.52
-7.17%
REPL Replimune Group, Inc.
8.37
-11.58%